Resected Pancreatic Ductal Adenocarcinoma (PDAC) research hub

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

This study looks at a new drug, daraxonrasib, for people with a type of pancreatic cancer that has been removed by surgery. It aims to see if the drug helps prevent the cancer from coming back compared to standard care.